Phase III pulmonary fibrosis drug trial fails
Bellerophon Therapeutics has announced it will close its Phase III study of INOpulse, its treatment for fibrotic Interstitial Lung Disease (fILD), after the trail failed to meet its primary endpoint. The REBUILD clinical trial was designed as a randomised, double-blind, placebo-controlled Phase III study evaluating the… Read More